Aberrant kinase signalling: Lessons from head and neck cancer

Future Oncology

Volumn 3, Issue 3, 2007, Pages 353-361

  Nelson, Elizabeth G ^a   Grandis, Jennier R ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh School of Medicine   (United States)

Author keywords

Epidermal growth factor receptor; Head and neck cancer; Insulin like growth factor receptor; Receptor tyrosine kinases; Serine threonine kinases; Src family kinases

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; IMATINIB; NVP AEW 541; OSI 779; OSI 906; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; TEMSIROLIMUS; UNC 01; UNCLASSIFIED DRUG; VANDETANIB; WORTMANNIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RECEPTOR BLOCKING; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; DRUG ANTAGONISM; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34347404688     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.353     Document Type: Review

References (43)

1. Jernal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 56(2). 106-130 (2006).
2. Egloff AM, Grandis J: Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin. Ther. Targets 10(5), 639-647 (2006).
3. Cruz JJ, Ocana A, Del Barco E, Pandielia A: Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann. Oncol. 18(3), 421-430 (2006).
4. Chai RL, Grandis JR: Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr. Treat. Options Oncol. 7(1), 3-11 (2006).
5. Lin HS, Berry GJ, Fee WE Jr, Terris DJ, Sun Z: Identification of tyrosine kinases overexpressed in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 130 (3), 311-316 (2004).
6. Weinberg RA: The Biology of Cancer, Garland Publishing, NY, USA (2007).
7. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005).
8. Pomerantz RG, Grandis JR: The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin. Oncol. 31(6), 734-743 (2004).
9. Pomerantz RG, Grandis JR: The role of epidermal growth factor receptor in head and neck squamous, cell carcinoma. Curr Oncol. Rep. 5(2), 140-146 (2003).
10. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24(17), 2666-2672(2006).
11. Lynch TJ, Bell DW, Sordelia R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
12. Jimeno A, Kuiesza P, Wheelhouse J et al.: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br. J. Cancer 96(6), 952-959 (2007).
13. O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 38(7), 627-640 (2002).
14. Warren CM, Landgraf R: Signaling through ERBB receptors: multiple layers of diversity and control. Cell. Signal. 18(7), 923-933 (2006).
15. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319(1), 1-11 (2004).
16. Bel R, Budillon A, Masuelil L et al.: Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J. Pathol. 204(3), 317-325 (2004).
17. Erjaia K, Sundvall M, Junttila TT et al.: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 12(13), 4103-4111 (2006).
18. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
19. Adams TE, Epa VC, Garrett TP, Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 57(7), 1050-1093 (2000).
20. Slomiany MG, Black LA, Kibbey MM et al.: Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett. 248(2), 269-279 (2006).
21. Wu X, Zhao H, Do KA et al.: Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin. Cancer Res. 10(12 Pt 1), 3988-3995 (2004).
22. García-Echeverría C, Pearson MA, Marti A et al.: In vivo antitumor activity of NVP-AEW541: a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cells 5(3), 231-237 (2004).
23. Mariani SM: Targeting cancer cells - more pathways, more inhibitors, more trails. Highlights of 9th Annual Drug Discovery Technology World Congress. Boston. MA, USA, 8-13 August 2004. Med Gen Med 6(4). 22 (2004).
24. Allen GW, Saba C, Armstrong EA et al.: Insulin-like growth factor-1 receptor signaling blockade combined with radiation. Cancer Res. 67(3), 1155-1162 (2007).
25. Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4), 257-262 (2003).
26. Sekulic A, Hudson CC, Homme JL et al.: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60(13), 3504-3513 (2000).
27. Amornphimoltham P, Patel V, Sodhi A et al.: Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 65(21), 9953-9961 (2005).
28. Qiu W, Schonleben F, Li X et al.: PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 12(5), 1441-1446 (2006).
29. Kozaki K, Imoto I, Pimkhaokham A et al.: PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sri. 97(12), 1351-1358 (2006).
30. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc. Natl Acad. Sci. USA 98(20), 10983-10985 (2001).
31. Amornphimoltham P, Sriuranpong V, Patel V et al.: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. 10(12 Pt 1), 4029-4037 (2004).
32. Senderowicz AM: The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7(Suppl. 3), 12-19 (2002).
33. Noble MEM, Endicott JA, Johnson LN: Protein kinase inhibitors: insights into drug design from structure. Science 303(5665), 1800-1805 (2004).
34. Chu HR, Ongkeko WM. Diaz A et al: Growth inhibition of head and neck squamous cell carcinoma by imatinib mesylate (Gleevec). Cancer Ther. 3, 515-524 (2005).
35. Irby RB, Yeatman TJ: Role of Src expression and activation in human cancer. Oncogene 19(49), 5636-5642 (2000).
36. Frame MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 1602(2), 114-130 (2002).
37. Parsons SJ, Parsons JT: Src family kinases, key regulators of signal transduction. Oncogene 23(48), 7906-7909 (2004).
38. Johnson FM, Saigal B, Taipaz M, Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 11(19 Pt 1), 6924-6932 (2005).
39. Xi S, Zhang Q, Dyer KF et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. 278(34), 31574-31583 (2003).
40. Sriuranpong V, Park JI. Amornphimoltham P et al.: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 63(11), 2948-2956 (2003).
41. Plate KH, Breier G, Welch HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398). 845-848 (1992).
42. Ciardiello F, Caputo R, Damiano V et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546-1556 (2003).
43. Herbst R, Johnson B, Rowbottom J et al.: O-100 ZD6474 plus docetaxel In patients with previously treated NSCLC: results of a randomized, placebo-controlled Phase II trial. Lung Cancer 49(Suppl. 2), S35-S36 (2005).